Intravenous immunoglobulin therapy in a patient with lupus serositis and nephritis.
The use of intravenous immunoglobulin (IVIg) has been reported as an immunomodulating agent in several autoimmune diseases, including systemic lupus erythematosus (SLE). Herein we report a SLE patient with severe clinical presentation that included pericarditis, pleural effusion, nephrotic range proteinuria, leukopenia, and lymphopenia. The patient received one course of high-dose IVIg (2.8 g/kg body weight), and within a week of post-IVIg therapy, her condition significantly improved. One-month post-IVIg there were decreased proteinuria, elevated leukocytes and lymphocytes count, decrease in antinuclear and anti-dsDNA antibodies, and disappearance of pericarditis and pleuritis. This case demonstrates the efficacy of IVIg in severe SLE with various clinical manifestations.
Meissner
M
M
Department of Medicine B, Sheba Medical Center, Tel-Hashomer, Israel.
Sherer
Y
Y
Levy
Y
Y
Chwalinska-Sadowska
H
H
Langevitz
P
P
Shoenfeld
Y
Y
D000328:Adult; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000628:therapy*; D009393:Nephritis / Q000150:complications / Q000628:therapy*
D016756:Immunoglobulins, Intravenous